Hybio Pharmaceutical shareholders approve financing from Shenzhen Hi-Tech Investment

Shenzhen Hybio Pharmaceutical Co., Ltd. announced the resolutions from its Third Extraordinary General Meeting of Shareholders in 2025, held on November 6, 2025. The meeting, which combined in-person and online voting, saw 1,012 shareholders representing 206,360,091 shares, or 23.3640% of the company's voting shares, participate. The primary agenda item, "Proposal on Financing from Shenzhen Hi-Tech Investment Group Co., Ltd. and its Subsidiaries," was approved with significant support.

The financing proposal received 204,824,182 votes in favor, accounting for 99.2557% of the total effective voting shares present. There were 1,301,309 votes against (0.6306%) and 234,600 abstentions (0.1137%). For small and medium-sized shareholders, the approval rate was 93.1550%, with 20,902,460 votes in favor.

The meeting procedures, shareholder qualifications, and voting results were confirmed by GuoHao Law Firm (Shenzhen) to be in compliance with relevant laws and company articles, affirming the legality and validity of the resolutions. The company confirmed that no proposals were rejected or altered, and no prior general meeting resolutions were changed.